EA201490927A1 - Ингибиторы pak для лечения клеточно-пролиферативных расстройств - Google Patents

Ингибиторы pak для лечения клеточно-пролиферативных расстройств

Info

Publication number
EA201490927A1
EA201490927A1 EA201490927A EA201490927A EA201490927A1 EA 201490927 A1 EA201490927 A1 EA 201490927A1 EA 201490927 A EA201490927 A EA 201490927A EA 201490927 A EA201490927 A EA 201490927A EA 201490927 A1 EA201490927 A1 EA 201490927A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
cell
pak inhibitors
proliferative disorders
pak
Prior art date
Application number
EA201490927A
Other languages
English (en)
Inventor
Дэвид Кэмпбелл
Серджио Г. Дюрон
Original Assignee
Афраксис Холдингз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Афраксис Холдингз, Инк. filed Critical Афраксис Холдингз, Инк.
Publication of EA201490927A1 publication Critical patent/EA201490927A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В настоящей заявке представлены ингибиторы PAK и способы использования ингибиторов PAK для лечения клеточно-пролиферативных расстройств и/или расстройств ЦНС.
EA201490927A 2011-11-04 2012-11-02 Ингибиторы pak для лечения клеточно-пролиферативных расстройств EA201490927A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555902P 2011-11-04 2011-11-04
PCT/US2012/063413 WO2013067423A1 (en) 2011-11-04 2012-11-02 Pak inhibitors for the treatment of cell proliferative disorders

Publications (1)

Publication Number Publication Date
EA201490927A1 true EA201490927A1 (ru) 2014-10-30

Family

ID=48192852

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201490925A EA201490925A1 (ru) 2011-11-04 2012-11-02 Ингибиторы pak для лечения синдрома умственной отсталости, сцепленного с ломкой х хромосомой
EA201490927A EA201490927A1 (ru) 2011-11-04 2012-11-02 Ингибиторы pak для лечения клеточно-пролиферативных расстройств

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201490925A EA201490925A1 (ru) 2011-11-04 2012-11-02 Ингибиторы pak для лечения синдрома умственной отсталости, сцепленного с ломкой х хромосомой

Country Status (20)

Country Link
US (2) US20130116263A1 (ru)
EP (2) EP2773642A1 (ru)
JP (2) JP2014532724A (ru)
KR (2) KR20140096098A (ru)
CN (2) CN104039786A (ru)
AR (1) AR089175A1 (ru)
AU (2) AU2012327187A1 (ru)
BR (2) BR112014010631A2 (ru)
CA (2) CA2854471A1 (ru)
CL (2) CL2014001132A1 (ru)
CO (1) CO7030960A2 (ru)
CR (2) CR20140251A (ru)
EA (2) EA201490925A1 (ru)
IL (2) IL232154A0 (ru)
MA (2) MA35660B1 (ru)
MX (2) MX2014005292A (ru)
PH (1) PH12014500995A1 (ru)
SG (2) SG11201401996TA (ru)
TW (1) TW201326169A (ru)
WO (2) WO2013067434A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252967A1 (en) * 2010-06-10 2013-09-26 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
MX343893B (es) 2011-11-04 2016-11-28 Hoffmann La Roche Nuevos derivados de aril-quinolina.
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
EA036160B1 (ru) 2013-03-15 2020-10-08 Селджен Кар Ллс Гетероарильные соединения и их применение
WO2015011252A1 (en) * 2013-07-26 2015-01-29 F. Hoffmann-La Roche Ag Pyrimidine-pyridinone serine/threonine kinase inhibitors
PT3102577T (pt) * 2014-02-07 2018-10-23 Principia Biopharma Inc Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastos
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10694988B2 (en) * 2016-02-17 2020-06-30 Nuralogix Corporation System and method for detecting physiological state
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2017220516A1 (en) * 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
WO2018013466A2 (en) * 2016-07-15 2018-01-18 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of endocrine resistance in breast cancer
CN106818805A (zh) * 2016-12-27 2017-06-13 东莞市联洲知识产权运营管理有限公司 一种天然乙酰胆碱酯酶抑制剂及其杀虫应用
CN107083428B (zh) * 2017-04-10 2020-09-25 徐州医科大学 Pak5在癌症诊断预后治疗及药物筛选中的应用
US20220002429A1 (en) * 2018-10-24 2022-01-06 Northwestern University Tumor cell aggregation inhibitors' for treating cancer
WO2020142612A1 (en) * 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
CN112213400B (zh) * 2019-07-09 2022-06-07 四川弘合生物科技有限公司 一种β-榄香烯及其有关物质的检测方法
CN110496128B (zh) * 2019-09-23 2022-09-30 吉林大学 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc GCN2 and PERK kinase inhibitors and methods of using them
CN117858879A (zh) * 2021-01-15 2024-04-09 南京再明医药有限公司 Cdk2/4/6抑制剂及其制备方法和应用
CN113046323A (zh) * 2021-04-02 2021-06-29 四川农业大学 一种基于miR-532-5p及其靶基因调控卵巢颗粒细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
WO2008055842A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
EP2112150B1 (en) * 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
US8674095B2 (en) * 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
EP2486037A4 (en) * 2009-10-09 2013-01-16 Afraxis Inc 8-ETHYL-6- (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
WO2011156646A2 (en) * 2010-06-09 2011-12-15 Afraxis, Inc. 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
US20130252967A1 (en) * 2010-06-10 2013-09-26 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

Also Published As

Publication number Publication date
SG11201401996TA (en) 2014-05-29
CA2854462A1 (en) 2013-05-10
MA35660B1 (fr) 2014-11-01
CN104039786A (zh) 2014-09-10
US20130116263A1 (en) 2013-05-09
JP2015501786A (ja) 2015-01-19
JP2014532724A (ja) 2014-12-08
EP2773643A4 (en) 2015-07-29
AU2012327187A1 (en) 2013-05-23
MX2014005292A (es) 2014-09-11
CR20140250A (es) 2014-08-20
AU2012327183A1 (en) 2013-05-30
US20150031693A1 (en) 2015-01-29
KR20140096098A (ko) 2014-08-04
MA35661B1 (fr) 2014-11-01
IL232215A0 (en) 2014-06-30
CA2854471A1 (en) 2013-05-10
IL232154A0 (en) 2014-05-28
PH12014500995A1 (en) 2014-08-04
WO2013067434A1 (en) 2013-05-10
BR112014010631A2 (pt) 2017-04-25
EP2773642A1 (en) 2014-09-10
SG11201401914WA (en) 2014-05-29
AU2012327183A8 (en) 2013-07-18
MX2014005296A (es) 2014-08-27
EA201490925A1 (ru) 2014-09-30
CL2014001131A1 (es) 2014-08-22
WO2013067423A1 (en) 2013-05-10
CN104093717A (zh) 2014-10-08
AU2012327187A8 (en) 2013-07-25
AR089175A1 (es) 2014-08-06
TW201326169A (zh) 2013-07-01
CL2014001132A1 (es) 2014-08-22
CR20140251A (es) 2014-08-20
EP2773643A1 (en) 2014-09-10
KR20140105451A (ko) 2014-09-01
BR112014010420A2 (pt) 2017-04-25
CO7030960A2 (es) 2014-08-21

Similar Documents

Publication Publication Date Title
EA201490927A1 (ru) Ингибиторы pak для лечения клеточно-пролиферативных расстройств
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
DK2753334T3 (da) Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201500362A1 (ru) Ингибиторы rho-киназы
UY34105A (es) Formulación líquida estable de etanercept
PH12014501914A1 (en) Anti sez6 antibodies and methods of use
EA201491304A1 (ru) Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
IN2014CN03555A (ru)
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
EA201590018A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
EA201491894A1 (ru) Способы лечения непереносимости лактозы
DK3495495T3 (da) Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer